Olema Oncology
Morena Shaw has a comprehensive background in clinical pharmacology, spanning from their early career as a Graduate Student at the University of California San Diego to their current role as the Director of Clinical Pharmacology at Olema Oncology. Their experience includes positions such as Associate Director of Clinical Pharmacology at Certara and Associate Director of Pharmacology at AnaptysBio, where they led and managed various nonclinical and clinical pharmacology responsibilities. Throughout their career, Morena has been actively involved in supporting projects from early translational to late development stages, collaborating with internal and client teams on regulatory and clinical development issues. Additionally, they have contributed significantly to the advancement of therapeutic assets in areas such as oncology, neuroscience, and cardiovascular through their expertise in pharmacology and bioanalytical strategies.
Morena Shaw earned a Bachelor of Science (B.S.) in Molecular Biology from UC San Diego in 2000 and a Master of Science (MS) in Biology, General from the same institution in 2001. In addition to their degrees, they obtained various certifications, including a Regulatory Affairs Credential from UC San Diego in 2021 and Certara certifications in Pharmacokinetics and Population PK/PD Pharmacometrician.
This person is not in any offices
Olema Oncology
Olema Oncology is a biopharmaceutical company developing innovative targeted therapies for women’s cancers. Their lead program, OP-1250, a potential best-in-class complete estrogen receptor antagonist (CERAN), is in development to treat estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Olema recently initiated a Phase 1/2 dose-escalation and expansion clinical trial of OP-1250. They are supported in their mission by experienced and accomplished scientists and board members, leading healthcare investors and some of the most innovative pharma companies.